The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management.
 
Hong Truong
No Relationships to Disclose
 
Rania Sheikh
No Relationships to Disclose
 
Yelena Kemel
No Relationships to Disclose
 
Manuel De Jesus Escano
No Relationships to Disclose
 
Aliya Khurram
No Relationships to Disclose
 
Peter Reisz
No Relationships to Disclose
 
Andrew Thomas Lenis
No Relationships to Disclose
 
Alvin C. Goh
No Relationships to Disclose
 
Eugene K. Cha
No Relationships to Disclose
 
Bernard H. Bochner
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche; Olympus
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - Clinical Care Options; EMD Serono; Intellisphere; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Adicet Bio; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Immunomedics; Infinity Pharmaceuticals; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Dean F. Bajorin
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Loxo; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Lilly; Pfizer; QED Therapeutics; Scorpion Therapeutics; Syros Pharmaceuticals; Vividion Therapeutics
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Allergan (I); Genentech/Roche (I); Gyroscope (I); Neurogene (I); Novartis (I); Optos (I); Regeneron (I); Regenxbio (I)
 
Alicia Latham
Other Relationship - Conquer Cancer Foundation
 
Kenneth Offit
Other Relationship - AnaNeo Therapeutics
 
Maria Isabel Carlo
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Jonathan Coleman
Travel, Accommodations, Expenses - Digital Angiography Reading Center (I)
Other Relationship - Steba Biotech
 
Hikmat A. Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Janssen Biotech; PAIGE.AI